(Q80460188)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17560695%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

title

Vaccinating adolescents against meningococcal disease in Canada: a cost-effectiveness analysis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17560695%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

main subject

Canada

0 references

meningococcal disease

1 reference

Philippe De Wals

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17560695%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Laurent Coudeville

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17560695%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Pierre Trottier

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17560695%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Catherine Chevat

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17560695%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Lonny J Erickson

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17560695%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Van Hung Nguyen

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17560695%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

publication date

15 May 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17560695%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17560695%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

volume

25

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17560695%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

issue

29

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17560695%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

page(s)

5433-5440

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17560695%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

cites work

Meningococcal disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.071

Immunization strategies for the control of serogroup C meningococcal disease in developed countries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.071

Meningococcal serogroup W135 in the African meningitis belt: epidemiology, immunity and vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.071

A review of vaccine research and development: meningococcal disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.071

Relative efficacy of different immunization schedules for the prevention of serogroup C meningococcal disease: a model-based evaluation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.071

Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.071

Impact and effectiveness of meningococcal C conjugate vaccine following its introduction in Spain.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.071

Mucosal immune responses to meningococcal group C conjugate and group A and C polysaccharide vaccines in adolescents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.071

Mucosal immune responses to meningococcal conjugate polysaccharide vaccines in infants.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.071

Dynamic models of meningococcal carriage, disease, and the impact of serogroup C conjugate vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.071

Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.071

Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.071

Evaluation of the completeness of reporting of invasive meningococcal disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.071

Meningococcal infections in children from Arkansas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.071

Complications of meningococcal disease in college students.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.071

Mathematical modelling of infection and disease due to Neisseria meningitidis and Neisseria lactamica.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.071

Economic analysis of the 1992-1993 mass immunization campaign against serogroup C meningococcal disease in Quebec

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.071

The societal costs of severe to profound hearing loss in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.071

Prospective analysis of global costs for maintenance of patients with ESRD.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.071

Health economics of a hexavalent meningococcal outer-membrane vesicle vaccine in children: potential impact of introduction in the Dutch vaccination program

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.071

Complications and sequelae of meningococcal disease in Quebec, Canada, 1990-1994.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.071

Cost-effectiveness of immunization strategies for the control of serogroup C meningococcal disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.071

Modelling cost effectiveness of meningococcal serogroup C conjugate vaccination campaign in England and Wales

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.071

Influence of serogroup on the presentation, course, and outcome of invasive meningococcal disease in children in the Republic of Ireland, 1995-2000.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.071

The EQ-5D and the Health Utilities Index for permanent sequelae after meningitis: a head-to-head comparison.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.071

Effectiveness of a mass immunization campaign using serogroup C meningococcal conjugate vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.071

10.1016/J.VACCINE.2007.04.071

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17560695%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

1 reference